Nektar Therapeutics NKTR EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Nektar Therapeutics’s reported figures.
The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nektar Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nektar Therapeutics's EBITDA?
- Nektar Therapeutics (NKTR) reported EBITDA of -$38.9M in Q1 2026.
- How has Nektar Therapeutics's EBITDA changed year-over-year?
- Nektar Therapeutics's EBITDA increased by 11.8% year-over-year, from -$44.11M to -$38.9M.
- What is the long-term trend for Nektar Therapeutics's EBITDA?
- Over 4 years (2021 to 2025), Nektar Therapeutics's EBITDA has grown at a -24.7% compound annual growth rate (CAGR), from -$431.96M to -$139.08M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.